Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility
March 22 2022 - 6:00AM
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the
Company”) a biopharmaceutical company developing vaccines, today
announced that their licensing partner, Cincinnati Children’s
Hospital Medical Center, or CCHMC, has published a research paper
entitled “Bioengineered pseudovirus nanoparticles displaying the
HA1 antigens of influenza viruses for enhanced immunogenicity” in
Nano Research. The company’s lead vaccine programs are focused on
developing transformational and novel vaccines against various
infectious diseases, including influenza and gastroenteritis by
norovirus or rotavirus infection.
The company’s norovirus shell and protrusion (S&P) platform
is currently being utilized to develop BWV-301, a vaccine for
gastroenteritis caused by norovirus or rotavirus infection. This
latest publication highlights the versatility of the S&P
platform beyond norovirus / rotavirus application and supports
BWV’s exploration of utilizing the novel S&P platform to
develop vaccine candidates against H1, H3, and Flu B
infections.
According to Ming Tan, Ph.D., the principal investigator of this
study, “Successful creation of HA1 influenza antigen PVNPs is a
critical step forward in the development of a stable, durable flu
vaccine.” He added, “This platform will allow us to investigate the
immunogenicity of pseudovirus nanoparticles (PVNPs) displaying
various antigenic combinations and assess the potential
effectiveness of each.”
The research describes new technology developed to generate a
unique HA1 norovirus based PVNP that displays the receptor-binding
HA1 antigens of influenza viruses (IVs). These PVNPs displaying the
HA1 antigens react with HA-specific antibodies and can be used as a
new reagent for influenza virus studies. Moreover, the proprietary
PVNPs provide a platform framework for designing multiple potential
vaccine candidates in addition to influenza, including the
norovirus/rotavirus vaccine candidate currently in the company’s
pipeline.
“This study is a great step forward for our S&P platform to
develop novel vaccines across a wide range of infections, including
influenza and gastroenteritis, which both represent significant
global health burdens that need effective management through
improved vaccines,” said Joseph Hernandez, CEO of BWV. “With our
partner at CCHMC, we look forward to the next stage of development
of this novel platform and exploration of various vaccine
development applications.”
In July 2021, Blue Water Vaccines entered an exclusive, global
licensing agreement with CCHMC to develop vaccines for multiple
infectious diseases utilizing the latter’s novel virus-like
particle (VLP) vaccine platform. The platform leverages norovirus
capsid proteins to present foreign antigens for immune enhancement.
This synergistic partnership leverages CCHMC’s scientific expertise
for BWV’s vaccine development.
According to the World Health Organization, there are normally
more than 1 billion influenza infections leading to 290,000 to
650,000 deaths each year, even with available vaccination efforts.
Current influenza vaccines are incredibly limited, relying on
annual review and potential reformulation based upon the predicted
circulation of specific strains. Additionally, the Centers for
Disease Control and Prevention reports that viral gastroenteritis
infections cause approximately 200,000 deaths in children worldwide
each year. While there are available vaccines for rotavirus
infection, there are currently no approved vaccines for norovirus
infection prevention.
About Blue Water VaccinesBlue Water Vaccines,
Inc. is a biopharmaceutical company focused on developing
transformational vaccines to address significant health challenges
globally. Headquartered in Cincinnati, OH, the company holds
the rights to proprietary technology developed at
the University of Oxford, Cincinnati Children's Hospital
Medical Center (CCHMC), and St. Jude Children's Hospital. The
company is developing a universal flu vaccine that will provide
protection from all virulent strains in addition to licensing a
novel norovirus (NoV) S&P nanoparticle versatile virus-like
particle (VLP) vaccine platform from CCHMC to develop vaccines for
multiple infectious diseases, including norovirus/rotavirus and
malaria, among others. Additionally, Blue Water Vaccines is
developing a Streptococcus pneumoniae (pneumococcus) vaccine
candidate, designed to specifically prevent the highly infectious
middle ear infections, known as Acute Otitis Media (AOM), in
children. For more information,
visit www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in
this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements are based on BWV’s current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, risks related to the
development of BWV’s vaccine candidates, including, but not limited
to BWV-301; the failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations; delays and uncertainties caused
by the global COVID-19 pandemic; risks related to the timing and
progress of clinical development of our product candidates; our
need for additional financing; uncertainties of patent protection
and litigation; uncertainties of government or third party payor
reimbursement; limited research and development efforts and
dependence upon third parties; and substantial competition. As with
any vaccine under development, there are significant risks in the
development, regulatory approval and commercialization of new
products. BWV does not undertake an obligation to update or revise
any forward-looking statement. Investors should read the risk
factors set forth in BWV’s registration statement on Form S-1
relating to its initial public offering, initially filed with the
Securities and Exchange Commission (the “SEC”) on October 10, 2021,
as amended, and periodic reports filed with the SEC on or after the
date thereof. All of BWV’s forward-looking statements are expressly
qualified by all such risk factors and other cautionary statements.
The information set forth herein speaks only as of the date
thereof.
Contact Information:Erin HendersonEmail:
ehenderson@bluewatervaccines.com
Olipriya Das (media)Email: olipriya.das@russopartnersllc.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Aug 2023 to Aug 2024